Sun Pharmaceutical Industries Limited (SUNPHARMA) announced today that UNLOXCYT® (cosibelimab-ipdl) has received a Category 2A recommended option in the updated National Comprehensive Cancer Network® (NCCN®) guidelines for locally advanced cutaneous squamous cell carcinoma (laCSCC) patients who are not candidates for curative surgery or curative radiation. This marks a significant milestone, reflecting the growing body of clinical evidence supporting UNLOXCYT.

Clinical Evidence and Patient Benefits

The evidence submitted to NCCN was based on the pivotal registration study, in which 55% of patients achieved an objective response, including 26% who achieved a complete response. Responses were durable with a median follow-up of 24.1 months and a median duration of response not yet reached. Importantly, fewer than 1% of patients experienced high-grade immune-mediated adverse reactions, which is crucial for this patient population.

Impact on Patient Access

The NCCN Guidelines play a vital role in helping physicians evaluate appropriate treatment options for patients across different disease settings. This designation ensures that appropriate patients can receive this treatment without unnecessary access barriers, offering a therapy that provides durable responses with a low rate of high-grade adverse reactions.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Sun Pharmaceutical Industries Limited

Sun Pharmaceutical Industries Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Sun falls 9.0% over three months and has not found a floor yet. The PEG reaches 3.29. The stock trades on brand and index weight, not on growth. Premium net margins of 20.2% demonstrate strong cost discipline and a wide competitive moat. The stock holds at 38% of its 52-week range with RSI at 37. In other words, neither side has a clear edge right now. Revenue grows at 10.4% and profits at 10.6% CAGR, with D/E of 0.03. Meanwhile, the stock dips 9.0% in three months without any fundamental deterioration. Consequently, the stock quietly becomes cheaper relative to earnings power. For long-term investors, that is a feature. Check Fundamentals of Sun Pharmaceutical Industries Limited.

Natco Pharma Limited (NSE: NATCOPHARM) announced the launch of Carboplatin Injection, a generic version of Paraplatin®, in the U.S. market by its subsidiary NATCO Pharma USA LLC. This launch, in manufacturing collaboration with Teyro Labs Pvt Ltd, aims to address a critical shortage of the product in the U.S. market. Carboplatin Injection is indicated for the treatment of advanced ovarian carcinoma, including first-line combination therapy and palliative treatment of recurrent disease after prior chemotherapy. The product had estimated sales of USD 27.8 million in the U.S. for the 12 months ending June 2026, according to industry sales data.

Strategic Collaboration

The collaboration with Teyro Labs Pvt Ltd, based in Chennai, is pivotal for the successful manufacturing and distribution of Carboplatin Injection. This strategic move underscores Natco Pharma’s commitment to expanding its oncology portfolio and addressing unmet medical needs in the U.S. market.

Market Impact

The launch of Carboplatin Injection is expected to significantly impact the oncology treatment landscape in the U.S. Natco Pharma Limited’s focus on limited competition molecules and its robust manufacturing capabilities position it as a key player in targeted therapies. With manufacturing facilities approved by leading regulatory authorities, Natco Pharma continues to cater to over 50 global markets.

As a result, Natco Pharma Limited’s launch of Carboplatin Injection marks a significant milestone in its ongoing efforts to provide essential medications to patients worldwide. For more information, visit www.natcopharma.com.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Natco Pharma Limited

Natco Pharma Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Natco drops 16.9% over three months and trades near its 52-week lows. The PEG of 0.48 is extremely low. Either the market misses the growth story, or there is a catch worth investigating. Industry-leading margins of 32.8% reflect exceptional pricing power and operational efficiency. The stock sits at 1% of its 52-week range, close to annual lows. Historically, value investors build positions at these levels — though cheap stocks can stay cheap. Revenue grows at 14.5% and profits at 25.6% CAGR, with D/E of 0.00. Meanwhile, the stock dips 16.9% in three months without any fundamental deterioration. Consequently, the stock quietly becomes cheaper relative to earnings power. For long-term investors, that is a feature. Check Fundamentals of Natco Pharma Limited.

Alembic Pharmaceuticals Limited (Alembic) announced today that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Ciprofloxacin and Dexamethasone Otic Suspension USP, 0.3% / 0.1%. This marks a significant milestone for the company, as the approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Ciprodex Otic Suspension, 0.3% / 0.1%, of Sandoz Inc. This approval will enable Alembic to offer an affordable treatment option for infections caused by susceptible microorganisms in both acute otitis media and acute otitis externa.

Market Potential

According to IQVIA, the estimated market size for Ciprofloxacin and Dexamethasone Otic Suspension USP, 0.3% / 0.1%, was US$110 million for twelve months ending June 2026. This approval further strengthens Alembic’s position in the generic pharmaceutical market, showcasing its capability to bring high-quality, cost-effective medications to patients.

Company Overview

Alembic Pharmaceuticals Limited, headquartered in India, has been at the forefront of healthcare since 1907. As a vertically integrated research and development pharmaceutical company, Alembic manufactures and markets generic pharmaceutical products globally. With state-of-the-art research and manufacturing facilities approved by regulatory authorities in many developed countries, including the USFDA, Alembic continues to lead in branded generics in India.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Alembic moves sideways over three months, with neither buyers nor sellers taking control. Thin margins at 8.9% leave limited room for error — any demand softness or cost spike hits the bottom line hard. Not a single revenue dip or loss quarter in five years — this is a business built to last through cycles. Buyers show up with 1.5x the volume of sellers. Moreover, they dominated on 17 of recent sessions versus 13 for sellers — a healthy accumulation pattern. Revenue grows at 9.5% and profits at 25.4%, and the dividend yield stands at 1.51%. The business is in good shape. Moreover, a stock that does not move despite strong fundamentals often offers better value than one already priced for perfection. Check Fundamentals of Alembic Pharmaceuticals Limited.